News

Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome

January 06, 2020

Company Continues to Expect Top-line Data in First Half of 2020 REDWOOD CITY, Calif. , Jan. 06, 2020 (GLOBE ...

Read More

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results

November 13, 2019

REDWOOD CITY, Calif. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage ...

Read More

Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock

October 25, 2019

REDWOOD CITY, Calif. , Oct. 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), ...

Read More
Soleno – Home